Incretin Hormones and Diabetes Management

Incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play a vital role in glucose metabolism. They enhance insulin secretion, inhibit glucagon release, and promote satiety. In diabetes management, incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, have emerged as effective treatments. These agents help improve glycemic control while aiding in weight loss and cardiovascular protection. Ongoing studies continue to investigate their long-term effects and potential benefits in diverse diabetic populations.